Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population
- PDF / 1,116,613 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 41 Downloads / 205 Views
ORIGINAL ARTICLE
Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population Toshiyuki Tamai1 · Masayuki Kaneko1 · Mamoru Narukawa1 Received: 19 May 2020 / Accepted: 2 October 2020 © Japan Society of Clinical Oncology 2020
Abstract Background It is important to recognize regional and racial differences in drug efficacy and safety when performing multiregional clinical trials (MRCTs). To understand regional differences, we compared the efficacy results in Japanese patients and the overall population in the MRCTs of anticancer drugs. Methods All new approvals of oncology drugs in Japan from January 2009 to December 2018 were searched using the Pharmaceuticals and Medical Devices Agency web site to find phase 3 MRCTs for the analysis. As the supporting data source, a literature search was performed in PubMed and Google Scholar. Linear regression analysis was performed and Pearson correlation coefficients (r) were calculated to compare the overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) between Japanese patients and the overall population. Results Seventy MRCTs were identified. The correlation of hazard ratios (HRs) for OS between Japanese patients and the overall population was moderate (r = 0.45), and OS was 1.31 times longer in Japanese patients than in the overall population, although the correlation of median OS was strong (r = 0.91). The HRs for PFS were moderately correlated (r = 0.70) and the correlation of median PFS was strong (r = 0.90). The correlation of ORR was very strong (r = 0.96). Conclusion The PFS and ORR were consistent between Japanese patients and the overall population. A longer median OS was observed in Japanese patients. Our results would be a useful reference when planning and conducting MRCTs that include Japan for global simultaneous drug development. Keywords Anticancer · Multi-regional · Japan · Regional difference · Cancer · Oncology
Introduction Multi-regional clinical trials (MRCTs) are one of the most useful approaches for the global development of new pharmaceutical agents and many MRCTs for regulatory submission are currently ongoing. MRCTs have been most commonly conducted in oncology and related areas [1]. However, some studies have reported regional and racial differences in efficacy and safety profiles in patients receiving anticancer treatment. For example, among patients with non-small * Toshiyuki Tamai t2‑[email protected] Masayuki Kaneko [email protected]‑u.ac.jp Mamoru Narukawa [email protected]‑u.ac.jp 1
School of Pharmacy, Kitasato University, 5‑9‑1, Shirogane, Minato‑ku, Tokyo 108‑8641, Japan
cell lung cancer (NSCLC) treated with chemotherapy, Asian patients have longer overall survival (OS) than non-Asian patients and they also have a higher incidence of hematotoxicities [2]. With regard to immunotherapy, North American patients benefit more from programmed cell death protein-1 (PD-1) or PD-1 ligand inhibitors than European patients, although these treat
Data Loading...
